SIP sigma pharmaceuticals limited

0.510, page-5

  1. 76 Posts.
    I would agree.

    This elevated volume would need to occur over 5 or 6 sessions to be credible.

    But, for an acquirer what would the strategic value be? I can't see there being much competition for this asset at such an early stage and the risks involved.

    The board will want to continue its asset sales program rather than a full takeover and a takeover premium at these prices just doesn't make sense to me.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.